Back to News
Market Impact: 0.3
Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Anaphylm Update
Source: Nasdaq
Corporate EarningsCompany Fundamentals
Aquestive Therapeutics reported Q3 2026 revenue of $7.6 million, down from $12.8 million in Q3 2025, a decline of about 41%. The company attributed the decrease primarily to quarterly fluctuations in Suboxone product orders.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.30
Ticker Sentiment
AQST-0.40
More News
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- Qualcomm issues disappointing earnings forecast as memory shortage weighs on smartphone sales
- ‘Seismic’ blue wave triggers the sinking of oil prices, energy stocks, and the chances of power permitting reform
- Softbank’s $5.4 bln takeover of ABB robotics unit blocked by China- FT
- Nifty Bounces Back to Beat All of Asia on Foreign Flows, Earnings
- Snap shares fall over 10% on third-quarter earnings miss